Effects Of Strategy Training And PNF On Balance, Gait, And Independence In Parkinson's Disease

March 16, 2026 updated by: Riphah International University

Effects of Strategy Training Versus Proprioceptive Neuromuscular Facilitation Technique on Balance, Gait, and Functional Independence in Patients With Parkinson's Disease

This randomized controlled trial aims to compare the effects of Strategy Training and Proprioceptive Neuromuscular Facilitation (PNF) on balance, gait, and functional independence in patients with Parkinson's disease. Parkinson's disease leads to impaired motor function, reduced balance, and decreased independence. Physiotherapy interventions such as strategy-based training and PNF may help improve mobility and functional performance. Participants will be randomly assigned to two groups: one receiving Strategy Training and the other receiving PNF intervention. Outcome measures including balance tests, gait assessment, and functional independence scales will be evaluated before and after treatment. The study aims to determine which intervention is more effective in improving functional outcomes in Parkinson's disease patients.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
42

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000
        • Global hospital and dialysis center Lahore
        • Contact:
      • Lahore, Punjab Province, Pakistan, 54000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:Diagnosed with Parkinson's Disease. Aged 40 to 80 years UPDRS level should be 2 and score will be 20-60 Able to walk independently or with minimal assistance Cognitively able to follow instructions

Exclusion Criteria:Severe comorbidities (e.g., cardiovascular, neurological) Recent surgery (within the last 6 months) Recent changes in Parkinson's medication Currently participating in other clinical trials Uncontrolled symptoms of Parkinson's Disease (e.g., severe tremors) Contraindications to rehabilitation treatment Resting systolic blood pressure>160mmHgor<100mmHg and resting diastolic pressure>100mmHg<6mmHg

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group A: PNF Technique
Participants will undergo PNF techniques targeting the muscles involved in balance and gait. This may include diagonal patterns, facilitation techniques, and proprioceptive neuromuscular facilitation holds.
Other: PNF Technique
Participants will undergo PNF techniques targeting the muscles involved in balance and gait. This may include diagonal patterns, facilitation techniques, and proprioceptive neuromuscular facilitation holds.
Experimental: Group B: Strategy training
Strategy Training Group Participants will receive training in specific cognitive strategies to improve balance and gait. This will include visual cues, verbal instructions, and mental rehearsal techniques.
Other: Strategy Training
Strategy Training Group Participants will receive training in specific cognitive strategies to improve balance and gait. This will include visual cues, verbal instructions, and mental rehearsal techniques.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
10-Meter Walk Test (10MWT)
Time Frame: 6 weeks
The 10-Meter Walk Test (10MWT) is an effective instrument that is applied to determine the walking speed and functional mobility in different populations.
6 weeks
Tandem Stance Test
Time Frame: 6 weeks
Tandem Stance Test is one of the essential clinical tests of balance and postural stability particularly among older adults. It involves getting a person to stand on their heels to toes and this is used to determine people who are at risk of falling.
6 weeks
Pastor Test (Shoulder Tug)
Time Frame: 6 weeks
Pastor Test (Shoulder Tug test) is a test used to determine the shoulder stability (especially the anterior shoulder instability). In the test, the examiner pulls the patient using his arm as he keeps the shoulder constant to reveal too much movement or pain.
6 weeks
30 sec Chair Test
Time Frame: 6 weeks
30 sec Chair Test; A popular test for assessing lower body strength, balance, and functional mobility especially in older adults is the chair test. It gauges a person's capacity to carry out daily tasks on their own by timing how long it takes them to get up from a sitting position and sit down again.
6 weeks
Retropulsion Test
Time Frame: 6 weeks
Retropulsion Test is a clinical examination, which is mainly applied to determine the postural stability and balance in a person, particularly the people with Parkinson disease. In this test, the examiner smoothly pulls the shoulders of the patient in the standing position where the patient stands in a relaxed position, and the examiner sees whether the patient can balance or not.
6 weeks
Unified Parkinson's Disease Rating Scale (UPDRS)
Time Frame: 6 weeks
Unified Parkinson Disease Rating Scale (UPDRS) as one of the important assessment instruments in the study of Parkinson disease and its clinical application. (UPDRS) scale is a comprehensive tool, employed to assess treatment issues related to the treatment of the Parkinson disease, the daily life activities as well as the motor and non-motor symptoms.
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Arnab Altaf, MS-PT, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 16, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 16, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR&AHS/B43-098

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson's Disease (PD)

Clinical Trials on PNF Technique

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings